Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity
Antimicrobial Agents and Chemotherapy · 18.10.2023 · 67 (10)
DOI: 10.1128/aac.00636-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.10.2023. Verfasst von Miranda A Lewis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas, USA. Hauptthemen laut MEDLINE: Norovirus, Gastroenteritis, Caliciviridae Infections. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis. In immunocompetent hosts, symptoms usually resolve within 3 days; however, in immunocompromised persons, HuNoV infection can become persistent, debilitating, and sometimes life-threatening. There are no licensed therapeutics for HuNoV due to a near half-century delay in its cultivation. Treatment for chronic HuNoV infection in immunosuppressed patients anecdotally includes nitazoxanide, a broad-spectrum antimicrobial licensed for treatment of parasite-induced gastroenteritis. Despite its off-label use for chronic HuNoV infection, nitazoxanide has not been clearly demonstrated to be an effective treatment. In this study, we standardized a pipeline for antiviral testing using multiple human small intestinal enteroid lines representing different intestinal segments and evaluated whether nitazoxanide inhibits replication of five HuNoV strains in vitro . Nitazoxanide did not exhibit high selective antiviral activity against any HuNoV strain tested, indicating it is not an effective antiviral for HuNoV infection. Human intestinal enteroids are further demonstrated as a model to serve as a preclinical platform to test antivirals against HuNoVs to treat gastrointestinal disease. Abstr
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas, USA.
- Department of Medicine, Infectious Diseases, University of Nebraska Medical Center , Omaha, Nebraska, USA.
- Department of Medicine, Baylor College of Medicine , Houston, Texas, USA.
ORCID-Profile: Miranda A Lewis, Khalil Ettayebi, Robert L Atmar, Sasirekha Ramani, Mary K Estes
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NIDDK NIH HHS
- HHS | U.S. Public Health Service
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- HHS | NIH | National Institute of General Medical Sciences
Zitieren
APA
Lewis, M. A., Cortés-Penfield, N. W., Ettayebi, K., Patil, K., Kaur, G., Neill, F. H., Atmar, R. L., Ramani, S., & Estes, M. K. (2023). Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity. Antimicrobial Agents and Chemotherapy, 67(10). https://doi.org/10.1128/aac.00636-23
Vancouver
Lewis MA, Cortés-Penfield NW, Ettayebi K, Patil K, Kaur G, Neill FH, et al. Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity. Antimicrobial Agents and Chemotherapy. 2023;67(10). doi:10.1128/aac.00636-23
BibTeX
@article{Lewis2023,
author = {Lewis, Miranda A and Cortés-Penfield, Nicolás W and Ettayebi, Khalil and Patil, Ketki and Kaur, Gurpreet and Neill, Frederick H and Atmar, Robert L and Ramani, Sasirekha and Estes, Mary K},
title = {Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
volume = {67},
number = {10},
doi = {10.1128/aac.00636-23}
}
EUVIMED